Get started
Author

Marinus van Marwijk Kooij

Observed names: Kooij, Marinus van Marwijk, Marinus Van Marwijk Kooij
Institution: Isala
OpenAlex ID: A5111665123
Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK)
2012 · Gert J. Ossenkoppele, Georg Stussi, et al. · Blood · 76
PDF
Comparison of Three Radiation Dose Levels after EBVP Regimen in Favorable Supradiaphragmatic Clinical Stages (CS) I-II Hodgkin’s Lymphoma (HL): Preliminary Results of the EORTC-GELA H9-F Trial.
2005 · Houchingue Eghbali, Pauline Brice, et al. · Blood · 56
Post-Transplantation Cyclophosphamide after Allogeneic Hematopoietic Stem Cell Transplantation: Results of the Prospective Randomized HOVON-96 Trial in Recipients of Matched Related and Unrelated Donors
2019 · Cornelis N. De Jong, Ellen Meijer, et al. · Blood · 47
Phase III Trial of 2-Weekly CHOP with Rituximab for Aggressive B-Cell Non-Hodgkin’s Lymphoma in Elderly Patients.
2006 · Pieter Sonneveld, Wim van Putten, et al. · Blood · 17
Randomized Maintenance Therapy with Azacitidine (Vidaza) in Older Patients (>= 60 years of age) with Acute Myeloid Leukemia (AML) and Refractory Anemia with Excess of Blasts (RAEB, RAEB-t). Results of the HOVON97 Phase III Randomized Multicentre Study (EudraCT 2008-001290-15)
2017 · Geert A. Huls, Dana Chiţu, et al. · Blood · 6
Alemtuzumab-CHOP for Aggressive T Cell Lymphoma. A Phase II HOVON 69 Trial.
2008 · J.C. Kluin-Nelemans, Marinus Van Marwijk Kooij, et al. · Blood · 5
Prospective Molecular MRD Detection By NGS: A Powerful Independent Predictor for Relapse and Survival in Adults with Newly Diagnosed AML
2017 · Mojca Jongen-Lavrencic, Tim Grob, et al. · Blood · 4
Bortezomib-Based Induction and Maintenance Overcomes the Negative Prognostic Impact of Renal Impairment and del17p in Transplant-Eligible Myeloma Patients: Long Term Results from the Phase III HOVON-65/GMMG-HD4 Study after Median 137 Months Follow up
2019 · Christof Scheid, Henk Lokhorst, et al. · Blood · 3
Time-Restricted Versus Standard Duration Immunosuppression after Allogeneic Hematopoietic Stem Cell Transplantation: Results from the Prospective Randomized Phase III HOVON-96 Trial
2019 · Cornelis N. De Jong, Ellen Meijer, et al. · Blood
Works count: 10
Citation count: 214
H-index: 5
I10-index: 4
Year
Topic
Type